Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 352

1.

Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.

Akazawa D, Moriyama M, Yokokawa H, Omi N, Watanabe N, Date T, Morikawa K, Aizaki H, Ishii K, Kato T, Mochizuki H, Nakamura N, Wakita T.

Gastroenterology. 2013 Aug;145(2):447-55.e1-4. doi: 10.1053/j.gastro.2013.05.007. Epub 2013 May 11.

PMID:
23673355
2.

Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.

Beaumont E, Patient R, Hourioux C, Dimier-Poisson I, Roingeard P.

Hepatology. 2013 Apr;57(4):1303-13. doi: 10.1002/hep.26132. Epub 2013 Mar 14.

3.

Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.

Cao J, Chen Z, Ren Y, Luo Y, Cao M, Lu W, Zhao P, Qi Z.

Vaccine. 2011 May 9;29(20):3714-23. doi: 10.1016/j.vaccine.2011.02.083. Epub 2011 Mar 9.

PMID:
21396407
4.
5.

[Study of neutralization antibodie induced by DNA vaccine of HCV envelope protein 2 in mice].

Shao S, Zhou H, Tong Y, Ren Y, Chen Z.

Wei Sheng Yan Jiu. 2011 May;40(3):295-8. Chinese.

PMID:
21695897
6.

N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.

Ren Y, Min YQ, Liu M, Chi L, Zhao P, Zhang XL.

Biochim Biophys Acta. 2016 Aug;1860(8):1764-75. doi: 10.1016/j.bbagen.2015.08.007. Epub 2015 Aug 14.

PMID:
26278021
7.

Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.

Deng K, Liu R, Rao H, Jiang D, Wang J, Xie X, Wei L.

PLoS One. 2015 Sep 25;10(9):e0138756. doi: 10.1371/journal.pone.0138756. eCollection 2015.

8.

Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.

Abe Y, Aly HH, Hiraga N, Imamura M, Wakita T, Shimotohno K, Chayama K, Hijikata M.

Gastroenterology. 2013 Sep;145(3):658-67.e11. doi: 10.1053/j.gastro.2013.05.014. Epub 2013 May 16.

PMID:
23684750
9.

New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.

Kachko A, Kochneva G, Sivolobova G, Grazhdantseva A, Lupan T, Zubkova I, Wells F, Merchlinsky M, Williams O, Watanabe H, Ivanova A, Shvalov A, Loktev V, Netesov S, Major ME.

Vaccine. 2011 Dec 9;30(1):69-77. doi: 10.1016/j.vaccine.2011.10.045. Epub 2011 Oct 29.

PMID:
22041300
10.

Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation.

Martinez-Donato G, Amador-Cañizares Y, Alvarez-Lajonchere L, Guerra I, Pérez A, Dubuisson J, Wychowsk C, Musacchio A, Aguilar D, Dueñas-Carrera S.

Vaccine. 2014 Mar 26;32(15):1720-6. doi: 10.1016/j.vaccine.2014.01.046. Epub 2014 Jan 30.

PMID:
24486345
11.

Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2.

El Abd YS, Tabll AA, El Din NG, Hosny Ael-D, Moustafa RI, El-Shenawy R, Atef K, El-Awady MK.

Virol J. 2011 Aug 5;8:391. doi: 10.1186/1743-422X-8-391.

12.

Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.

Doerrbecker J, Friesland M, Riebesehl N, Ginkel C, Behrendt P, Brown RJ, Ciesek S, Wedemeyer H, Sarrazin C, Kaderali L, Pietschmann T, Steinmann E.

Hepatology. 2014 Aug;60(2):508-20. doi: 10.1002/hep.27190. Epub 2014 Jun 24.

PMID:
24771613
13.

A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.

Kosaka K, Hiraga N, Imamura M, Yoshimi S, Murakami E, Nakahara T, Honda Y, Ono A, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Aikata H, Ochi H, Ishida Y, Tateno C, Yoshizato K, Sasaki T, Chayama K.

Biochem Biophys Res Commun. 2013 Nov 8;441(1):230-5. doi: 10.1016/j.bbrc.2013.10.040. Epub 2013 Oct 16.

PMID:
24140055
14.

Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.

Heile JM, Fong YL, Rosa D, Berger K, Saletti G, Campagnoli S, Bensi G, Capo S, Coates S, Crawford K, Dong C, Wininger M, Baker G, Cousens L, Chien D, Ng P, Archangel P, Grandi G, Houghton M, Abrignani S.

J Virol. 2000 Aug;74(15):6885-92.

15.

Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.

Lange M, Fiedler M, Bankwitz D, Osburn W, Viazov S, Brovko O, Zekri AR, Khudyakov Y, Nassal M, Pumpens P, Pietschmann T, Timm J, Roggendorf M, Walker A.

PLoS One. 2014 Jul 11;9(7):e102235. doi: 10.1371/journal.pone.0102235. eCollection 2014.

16.

Progress toward development of a hepatitis C vaccine with broad shoulders.

Ray R.

Sci Transl Med. 2011 Aug 3;3(94):94ps33. doi: 10.1126/scitranslmed.3002772.

PMID:
21813753
17.
18.
19.

Expression, purification, immunological characterization and application of Escherichia coli-derived hepatitis C virus E2 proteins.

Liu J, Zhu L, Zhang X, Lu M, Kong Y, Wang Y, Li G.

Biotechnol Appl Biochem. 2001 Oct;34(Pt 2):109-19.

PMID:
11592917
20.

Immunization With a Subunit Hepatitis C Virus Vaccine Elicits Pan-Genotypic Neutralizing Antibodies and Intrahepatic T-Cell Responses in Nonhuman Primates.

Li D, Wang X, von Schaewen M, Tao W, Zhang Y, Heller B, Hrebikova G, Deng Q, Sun Q, Ploss A, Zhong J, Huang Z.

J Infect Dis. 2017 Jun 15;215(12):1824-1831. doi: 10.1093/infdis/jix180.

PMID:
28398489

Supplemental Content

Support Center